Clinical Trial Update: Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

Clinical trial update of a Phase 3 study comparing sequential sunitinib and sorafenib in metastatic renal cell carcinoma; status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Yamagata University | Conditions: Metastatic Renal Cell Carcinoma | Phase 3 | Status: UNKNOWN